There was a statistically significant improvement in the overall response rate (ORR) for the combination compared to historical controls like anti-PD-1/PD-L1 and anti-CTLA4 drugs, while BNT111 and ...

The greatest benefit was seen in patients whose tumours expressed high levels of PD-L1, with an ORR of 80% and six-month PFS of 93%, which for those with low levels of the biomarker came in at 46% ...

Solnerstotug showed a 14% response rate and 62% disease control in PD-L1 resistant tumors, surpassing typical expectations. Significant responses were observed in Merkel cell carcinoma and ...

The investigational immuno-oncology combination demonstrates an overall response rate (ORR) of 26.9% and disease control rate (DCR) of 57.7% in 26 patients whose tumors do not express PD-L1 ...

The PD-L1 IHC 22C3 PharmDx (Code SK006) assay is now certified for use to aid treatment decisions for patients with gastric or gastroesophageal junction adenocarcinoma.